Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed \>/= 1 but \< 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15.

\*Study is officially closed on 08 Feb 2021\*
Chemotherapy-induced Neutropenia
DRUG: Plinabulin|DRUG: Pegfilgrastim|OTHER: Saline Placebo|OTHER: D5W Placebo
Duration of Severe Neutropenia (DSN), Duration of severe neutropenia (ANC \< 0.5 × 109/L), 21 Days
Change in Estimated Mean Bone Pain Score, Change in estimated mean bone pain score from pre-dose Day 1 through Day 8. The bone pain scale assessment was based on the validated Wong-Baker Faces® Pain Rating Scale. The pain scale range is from 0 to 10. The severity of pain marked on a scale is from 0 ('no hurt') to 10 ('hurt worst')., Day 1 through 8 in Cycle 1 (each cycle is 21 days)|Change in Patients With at Least 30% Platelet Count From Baseline in Cycle 1, Patients with platelet count at least 30% change from baseline at any time during Cycle 1, Anytime during Cycle 1 (each cycle is 21 days)|Proportion of Patients With Neutrophil-to-lymphocyte Ratio (NLR) > 5, Proportion of patients with neutrophil-to-lymphocyte ratio (NLR) \> 5 from Day 1 through Day 15, 15 Days|Proportion of Patients With Thrombocytopenia, Proportion of patients with thrombocytopenia (all grade) during 4 cycles, 84 days|Infections, Incidence of infections in cycles 1 to 4, 84 Days|Antibiotic Use, Incidence of antibiotic use, 21 Days|Sepsis, To assess the incidence of sepsis, 84 Days
Arm 1: Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin

Arm 2: Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim